Merck reports trial results. Scotiabank raises target for Merck stock

{
  "signal_id": "cf59187b-4ba4-bfa6-859b-f742fac81b00",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-02T15:29:02+00:00",
  "company": {
    "name": "Merck",
    "domain": "merck.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/merck-reports-trial-results-scotiabank-raises-target-for-merck-stock/70216563",
    "title": "Merck reports trial results. Scotiabank raises target for Merck stock - AD HOC NEWS",
    "excerpt": "Merck & Co. (ISIN US58933Y1055) reported positive phase 2b results for tulisokibart on September 30, 2026, while Scotiabank raised its price target from USD 155.00 to USD 180.00 on September 29, 2026. The combination gives investors two distinct signals: a development milestone in immunology and a higher valuation benchmark from an analyst house. According to Merck.com on September 30, 2026, the high-dose tulisokibart group achieved a 72.00 percent HiSCR50 response rate at week 16, compared with 35.00 percent for placebo. The medium-dose group reached 64.00 percent, giving Merck two dose levels that exceeded the primary endpoint. The result also supplied a concrete comparison for the program's next stage. HiSCR75 reached 41.00 percent in the high-dose group and 15.00 percent with placebo, a 26.00 percentage-point difference, while serious adverse events occurred in 2.40 percent of high-dose patients and 2.30 percent of placebo patients. MarketBeat reported on September 29, 2026 that Scotiabank lifted its Merck target to USD 180.00 from USD 155.00 and maintained a sector outperform rating. The increase was USD 25.00, or 16.13 percent, based on the previous target. MarketBeat also cited second-quarter 2026 adjusted earnings per share of negative USD 0.13 versus a negative USD 0.26 consensus estimate, while revenue reached USD 16.61 billion against USD 16.37 billion expected. The...",
    "product": "tulisokibart",
    "summary": "Merck & Co. reported positive phase 2b trial results for its drug candidate tulisokibart, with the high-dose group achieving a 72% response rate compared to 35% for placebo.",
    "planning": true,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2696917_1920_1080.webp",
    "confidence": 0.9,
    "product_data": {
      "name": "tulisokibart",
      "full_text": "tulisokibart",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-02T15:29:02Z",
    "effective_date": "2026-09-30",
    "article_sentence": "Merck & Co. (ISIN US58933Y1055) reported positive phase 2b results for tulisokibart on September 30, 2026, while Scotiabank raised its price target from USD 155.00 to USD 180.00 on September 29, 2026."
  }
}

curl https://signals.autobound.ai/v1/signals/cf59187b-4ba4-bfa6-859b-f742fac81b00 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"merck.com","limit":20}'